- Home
- SEVN vs CRBP Comparison
SEVN vs CRBP Comparison
Compare SEVN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | CRBP |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 184.4M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SEVN | CRBP |
|---|---|---|
| Price | $8.43 | $8.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.50 | ★ $45.50 |
| AVG Volume (30 Days) | 82.8K | ★ 671.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | $4,822,272.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | $116.00 |
| P/E Ratio | $44.21 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $7.90 | $6.73 |
| 52 Week High | $12.85 | $20.56 |
Technical Indicators
Market Signals| Indicator | SEVN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 44.89 |
| Support Level | $8.33 | $7.62 |
| Resistance Level | $8.83 | $8.54 |
| Average True Range (ATR) | 0.17 | 0.58 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.67 | 38.19 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.